Group 1 - The core point of the article is that Huatai Medical has announced the acquisition of a medical device registration certificate for "Polyvinyl Alcohol Embolization Microspheres" through its wholly-owned subsidiary, Hunan Apt Medical Devices Co., Ltd [1] - As of November 18, Huatai Medical's market capitalization is 38.2 billion yuan [3] - For the year 2024, Huatai Medical's revenue composition is projected to be 99.2% from medical devices and 0.8% from other businesses [2]

证券代码：688617 证券简称：惠泰医疗 公告编号：2025-051 深圳惠泰医疗器械股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述产品后续实际销售情况取决于未来市场的推广效果，公司目前尚无法预 测上述产品对公司未来营业收入的影响，敬请广大投资者理性投资、注意投资风 险。 特此公告。 深圳惠泰医疗器械股份有限公司董事会 2025 年 11 月 19 日 | 注册人名称 | 湖南埃普特医疗器械有限公司 | | --- | --- | | 产品名称 | 聚乙烯醇栓塞微球 | | 注册分类 | 第三类无源医疗器械 | | 注册证编号 | 国械注准 20253132312 | | 预期用途 | 该产品适用于富血管型实质型器官恶性肿瘤的栓塞治疗。 | 一、医疗器械注册证的具体情况 二、对公司的影响 上述医疗器械注册证的取得，有利于丰富公司的产品种类，扩充公司在外周 领域的产品布局，不断满足多元化的临床需求，进一步增强公司的核心竞争能力。 三、风险提示 近日，深圳惠泰医疗器械 ...

Core Viewpoint - Huitai Medical's wholly-owned subsidiary, Hunan Apt Medical Devices Co., Ltd., has recently obtained the registration certificate for "Polyvinyl Alcohol Embolization Microspheres," classified as a Class III non-active medical device, which is intended for embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The acquisition of the registration certificate enhances the company's product variety and expands its peripheral product layout [1] - This development is expected to strengthen the company's core competitiveness in the medical device industry [1] - However, the actual sales performance of the product will depend on market promotion effectiveness, and the company is currently unable to predict its impact on future revenue [1]

Core Viewpoint - Huitai Medical (688617) announced that its wholly-owned subsidiary, Hunan Apt Medical Devices Co., Ltd., has obtained a medical device registration certificate for a product named Polyvinyl Alcohol Embolization Microspheres, which is intended for the embolization treatment of hypervascular solid organ malignancies [1] Group 1 - The product is specifically designed for treating hypervascular solid organ tumors [1] - The registration certificate signifies a regulatory milestone for the company, potentially expanding its product offerings in the medical device market [1]

Core Viewpoint - Huatai Medical's subsidiary, Hunan Apt Medical Devices Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for a product named Polyvinyl Alcohol Embolization Microspheres, intended for embolization treatment of hypervascular solid organ malignancies [2] Group 1: Product Development - The acquisition of the medical device registration certificate will enrich the company's product variety and expand its product layout in the peripheral field [2] - The new product aims to meet diverse clinical needs, thereby enhancing the company's core competitiveness [2] Group 2: Market Impact - The actual sales performance of the new product will depend on future market promotion efforts [2] - The company is currently unable to predict the impact of this product on future operating income [2]

Core Viewpoint - Huitai Medical (688617.SH) announced that its wholly-owned subsidiary, Hunan Apt Medical Devices Co., Ltd., has obtained a medical device registration certificate for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular solid organ malignancies [1] Group 1 - The product is specifically designed for the treatment of hypervascular solid organ tumors [1] - The registration certificate signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the medical device sector [1]

Investment Rating - The report continues to recommend the innovative drug and medical device industry chain, indicating a high level of investment interest in this sector [1][5]. Core Views - The report highlights the high prosperity in innovative drugs, suggesting potential value revaluation for companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [2][5]. - It emphasizes the importance of Biopharma/Biotech companies with innovative pipelines and performance entering a volume increase phase, including Innovent Biologics, BeiGene, and others [2][5]. - The report also points out the recovery potential for leading medical equipment companies like United Imaging Healthcare, Lepu Medical, and others [2][5]. Summary by Sections A-Shares Performance - In the second week of November 2025, the A-Shares pharmaceutical sector outperformed, with the SW Pharmaceutical and Biological index rising by 3.3% while the SHCOMP fell by 0.2% [2][30]. - The pharmaceutical commerce, chemical raw materials, and chemical preparations sub-sectors showed strong performance, with increases of 5.7%, 5.1%, and 4.4% respectively [2][30]. - Notable stock gains included GDK (+61.6%), HPGC Renmintongtai Pharmaceutical Corporation (+61.1%), and Chengda Pharmaceuticals Co., Ltd. (+58.3%) [2][30]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also outperformed, with the Hang Seng Healthcare index increasing by 6.8% and the Hong Kong Biotechnology index by 7.1% [2][31]. - In the U.S., the S&P Healthcare Select Sector rose by 3.9%, significantly outperforming the S&P 500, which only increased by 0.1% [2][32]. Valuation Metrics - As of November 14, 2025, the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 77.0% [2][15]. - The report provides earnings forecasts and valuation metrics for various companies, indicating expected growth rates and price-to-earnings ratios for the coming years [6][7].

关于参加2025年度深圳辖区上市公司投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，深圳惠泰医疗器械股份有限公司（以下简称"公司"）将参加由深圳 证监局和中证中小投资者服务中心指导、深圳上市公司协会与深圳市全景网络有限公司联合举办 的"2025年度深圳辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 证券代码：688617 证券简称：惠泰医疗 公告编号：2025-050 董事会 深圳惠泰医疗器械股份有限公司 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站（http://rs.p5w.net），或关注微信 公众号：全景财经，或下载全景路演APP，参与本次互动交流，活动时间为2025年11月20日（周四） 14:30-17:00。届时公司管理层将在线就公司业绩、公司治理、发展战略、经营状况、可持续发展等投资 者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 深圳惠泰医疗器械股份有限公司 2025年11月15日 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688617 证券简称：惠泰医疗 公告编号：2025-050 深圳惠泰医疗器械股份有限公司 关于参加 2025 年度深圳辖区上市公司投资者 网上集体接待日活动的公告 深圳惠泰医疗器械股份有限公司董事会 2025 年 11 月 15 日 为进一步加强与投资者的互动交流，深圳惠泰医疗器械股份有限公司（以下 简称"公司"）将参加由深圳证监局和中证中小投资者服务中心指导、深圳上市 公司协会与深圳市全景网络有限公司联合举办的"2025 年度深圳辖区上市公司 投资者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 11 月 20 日（周四）14:30-17:00。届时公 司管理层将在线就公司业绩、公司治理、发展战略、经营状况、可持续发展等投 资者关心的问题，与投资者进行沟通与交流，欢 ...

证券之星消息，截至2025年11月13日收盘，惠泰医疗(688617)报收于279.0元，下跌2.15%，换手率0.5%，成交量6989.0手，成交额1.96亿元。 11月13日的资金流向数据方面，主力资金净流出126.77万元，占总成交额0.65%，游资资金净流入280.16万元，占总成交额1.43%，散户资金净流 出153.39万元，占总成交额0.78%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-13 | 279.00 | -2.15% | -126.77万 | -0.65% | 280.16万 | 1.43% | -153.39万 | -0.78% | | 2025-11-12 | 285.13 | 0.75% | -1182.58万 | -6.55% | 1292.24万 | 7.16% | -109.66万 | -0.61% | | 2025-11-11 | 2 ...